DISCLAIMERSCAUTION CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements in this presentation may contain “forward-looking

information,” within the meaning of applicable securities laws, including the

Securities Act (Ontario) with respect to Maricann Group Inc. (“Maricann” or the

“Company”). Such statements include, but are not limited to, statements with

respect to expectations, projections, or other characterizations of future events

or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans,

estimates, projections and outlook, including statements relating to our

expectation with respect to our expansion project, including the expected

increase in production, expected production cost and timing of commencement

and completion of our Phase II and Phase III expansion, expectations with respect

to expanding activities in Germany and elsewhere, future growth plans,

including, but not limited to, plans for European expansion, anticipated timing for

receiving certain licenses and certifications, including with respect to

exportation/importation to and in Germany and wholesale activities in Germany,

expectations with respect to the renewal of licenses, expectations with respect to

increased production capacity and timing and quantum of distribution activities;

medical benefits, viability, safety, efficacy, and social acceptance of cannabis,

expectations in respect to anticipated trends and challenges in the Company’s

industry, its business and the markets in which it operates, commentaries related

to legalization of marijuana and time related thereto, and our other plans and

objectives, or estimates or predictions of actions of customers, suppliers,

competitors or regulatory authorities. These statements are subject to certain

risks, assumptions and uncertainties that could cause actual results to differ

materially from those included in the forward- looking statements. The words

“believe”, “plan”, “intend”, “estimate”, “expect”, or “anticipate”, and similar

expressions, as well as future or conditional verbs such as “will”, “should”,

“would”, and “could” often identify forward-looking statements. We have based

these forward- looking statements on our current views with respect to future

events and financial performance. With respect to forward looking statements

contained in this Presentation, the Company has made assumptions and applied

certain factors regarding, among other things: future cannabis pricing; cannabis

production yields; costs of inputs; its ability to market products successfully to its

anticipated clients; reliance on key personnel; the regulatory requirements; the

application of federal and provincial environmental laws; and the impact of

increasing competition. In the case of the Company’s expected designed

production capacity for the future phases of its expansion project facility, the

expectations of management are based on the designs and plans of the new

facility, experience based on production at its current facility, and assumes it will

be successfully completed, licensed and operate as planned.

These forward-looking statements are also subject to the risks and uncertainties

some of which are discussed in the “Risks Factors” sections and elsewhere in the

Company’s annual information form dated June 19, 2018, its short form

prospectus dated March 28, 2018 and other risks detailed from time to time in the

other publicly filed disclosure documents of the Company which are available at

www.sedar.com. Forward-looking statements are not guarantees of future

performance and involve risks, uncertainties, and assumptions which could cause

actual results to differ materially from the conclusions, forecasts, or projections

anticipated in these forward-looking statements. Because of these risks,

uncertainties, and assumptions, the reader should not place undue reliance on

these forward-looking statements. The Company’s forward-looking statements

are made only as of the date of this presentation, and except as required by

applicable law, Maricann undertakes no obligation to update or revise these

forward-looking statements to reflect new information, future events or

circumstances.

Additional information regarding Maricann Group Inc. is available on

our website at www.maricann.com or through the SEDAR website at

www.sedar.com.

2

G L O B AL D E M AN D

$180 BILLION 3

Global Medical Market

$8.7 BILLION 2

Canadian Recreational Market

$1.3 BILLION1

Canadian Medical Market

1. . 2024 , Health Canada2.. Deloitte,“ Recreational Marijuana Insights and Oppor tunities”. 3 . Various sources

3

G L O B A L P R E S E N C E

Geographically diverse with operations in Canada and Western Europe

CANADA - LangtonFacility

217,000 square feet of grow and production space with annual capacity to grow up to 36,000 kg1.

GERMANY - EbersbachFacility

Proposed 820,000 square feet of clean-room cultivation, processing, andextraction

SWITZERLAND - HaxxonAG

~60,000 square feet of facility for female hemp cultivation

Independantly secured Letter of Intent (LOI) with Malta Enterprise

1. Based on current production at existing facility adjusted to reflect 217,000 square foot facility2. Based on current production at existing facility adjusted to reflect 635,000 square foot facility

4

ITALY - SanMartino

MALTA - MaltaEnterprise

Joint Venture to build a vertically integrated producer with a research partnership with The University of Eastern Piedmont

C A P I TA L I Z I N G ON OP P OR T U N I T Y

Manitoba — MBLL

Supply agreement to make available for purchase at least 550 kg of various cannabis products

Ontario — OCS

Wayland will supply 37 listings with a wide range of sizes, formats and strains

ALBERTA — AGLC

Allocating up to 3,375 kg of cannabis product for the AB market within the first six months

BRITISH COLUMBIA — BCLDB

Entered into a memorandum of understanding (“MOU”) to initially supply approximately 3,622 kg of non-medical cannabis

5

E U R O P E AN G R OW TH M AR KE T S

LEGAL

MEDICAL ONLY

DECRIMINALIZED

ILLEGAL

ITALY

6

16,000 PATIENTS

Up from ~800 in 2016 to 16,000 currently

62%

Have qualified for full health

insurance reimbursement

INTEGRATED

Joint Venture to build a vertically integrated producer with a research partnership with the University of Eastern Piedmont

GROWING CBD MARKET

Existing operations in a suburb ofZurich; selling product into a fastgrowing CBD market

1. Based on current production at existing facility adjusted to reflect 217,000 square foot facility2. Based on current production at existing facility adjusted to reflect 635,000 square foot facility

FINISHED DOSE MANUFACTURING

Wayland entered into a non-binding LOI with

Malta Enterprise

NO 25% VAT

W OR L D L E A D I N G E F F IC IE NC Y IN P R OD U C T I O N

AI-DataGrow

Wecapturealldata:everydropof waterthat goes

to each plant, light cycles, nutrients, humidity,

temperature. We can build from this data to

optimize future production, perfecting the

environment and grow cycle, while removing the

risk of inconsistencies fromtheloss of key

individuals.

Rockwell Automation

We are the first to take standard off- the-

shelf automation and customize the

software to create an automated

cultivation facility. The Artificially

Intelligent Master Grower can efficiently

produce high quality product.

Energy Efficiencies

Natural gas cogeneration facility on site,

reduces electricity costs. All energy from one

source: heat, electricity, and CO2. All water is

recycled through a state-of-the-art biofilter,

only 10,000 liters of waste in a year

7

TE CH N O L O G I C AL D I F F E R E N T I ATI O N

We’ve brought the best of the pharmaceutical world to cannabis. VESIsorb is used in lipophilic drugs (fat soluble) around the world and

Wayland has the patent protected global rights for use with cannabis. With both medicinal and recreational applications for products

such as beverages, edibles, capsules, and transdermal products, VESIsorb provides for consistent and predictable dosing with rapid

onset and greater absorption.

Cannabinoids are oily molecules from the cannabis plant

Poorly absorbed cannabinoids can have unpredictable effects

When cannabinoids are ingested..

CANNABINOIDS

EFFECTS ACTIVE BLOOD CANNABINOID LEVEL

TIME

they tend to clump together in the digestive system

8

This clumping interferes with absorption

This technology mimics the body’s natural processes, providing higher and more immediate active levels of blood cannabinoids, more reliable rates of absorption

VESIsorb technology provides for a more evenly dispersal after ingestion

More uniform distribution meansthe drug can make contact withabsorptive membranes

Northern Harvest

Northern Harvest is a familiar brand for light users who may have experimented with cannabis in the past, but don’t consider themselves regular users.Northern Harvest groups strains under consumer-friendly product names that make it easy to choose the right product for any occasion, whether it’sat a backyard get-together with friends or before heading to a music festival.Northern Harvest is a brand that welcomes everyone with open arms and is always ready for a good time.

Kiwi

Kiwi makes it simple to enjoy cannabis in any occasion. Kiwi is a brand for beginner and novice users that explains cannabis concepts in a straightforward way, helping users learn about cannabis without condescension or confusing jargon. Kiwi’s products are equally simple, grouping strains under memorable product names that allow users to choose how they want to feel by analyzing terpenes and genetic profiles. This brand allows users to enter the category with low-THC and balanced strains.

High Tide

High Tide is a brand for experienced cannabis users who know what they want and are looking for high-THC strains. The High Tide products are strain-forward, because High Tide users know exactly what they want. High Tide focuses on premium strains witha high percentage of THC, appealing to experienced cannabis users who are looking for some of the most powerful cannabisavailable.

PORTFOLIO OF RECREATIONAL BRANDS

9

Lost at Seed

Lost at Seed is a brand that will excite cannabis aficionados looking for a remarkable experience. This brand prides itself on rare genetics, oftenwith an interesting backstory that adds to the mystique. Lost at Seed is a luxury offering for experienced users whocan recognize the opportunity to try something truly unique that may never be seen again. Coming soon.

Rare Dankness

Wayland is proud to partner with Rare Dankness as their exclusive distributor in Canada. Rare Dankness is a Colorado- based brand that specializes in elite and rare cannabis genetics, builton decades of experimentation and precise breeding. Rare Dankness is a globally recognized brand with a reputation for being the best (multi-time winner of the High TimesCannabis Cup). This will be a flagship offering in Wayland’s brand portfolio.

Solara C

Solara C is designed to offer the highest-quality CBD products for wellness-focused consumers. Solara C also pioneers innovative delivery methods, giving users a widevariety of options for how they consume cannabis.

PORTFOLIO OF RECREATIONAL BRANDS

10

G E R M A NY

11

Import and Narcotics Wholesale license to be issued in Q3 of 2018

Growing Markets

The German patient population is growing exponentially – Up to over 16,0001 patients from~800 in 2016

First Harvest

On August 3rd, 2018, Wayland’s European nutraceutical subsidiary MariPlant, commenced the harvest of approximately 405 acres of hemp.

Room to Grow

Proposed 820,000 square feet of clean-room cultivation, processing, and extraction. 164 hectares (~405 acres) of outdoor industrialhemp cultivation

Price Point

62% of patients have qualified for full health insurance reimbursement2

Delivery of Vesisorb CBD Capsules

On September 12th, 2018 Maricann shipped the first batch of Mariplant CBD capsules to be sold in Munich and the Greater Munich regionfollowed by a shipment on September 14th, 2018 to the Greater Cologne region.

Producing Results

Export of 9,000kg of EU-GMP certified cannabisflowers over a three year term. Wayland agreed tosupply Cannamedical Pharma GmbH, whois a licensed, privately owned importer and distributor of Cannabis in Germany to over 22,000 pharmacies.

S W I T ZE R L A N D

Wayland acquired HAXXON AG in May of 2018

Producing

Currently producing from a 60,000 square foot facility in Regensdorf, Switzerland just outside of Zurich

Scaling Up

Plans to upgrade the facility and increase production by a factor of 6

Coming Soon

Wayland will be launching our own line of hemp cigarettes in Q4 of 2018

12

1. Based on current production at existing facility adjusted to reflect 217,000 square foot facility2. Based on current production at existing facility adjusted to reflect 635,000 square foot facility

Phase 1

• 217,000 square feet of grow and production space with annual capacity to grow up to 36,000 kg1

• Phase One will be fully operational in Q4 of 2018

Phase 2

• Additional 635,000 square feet of grow space bring annual capacity up to 105,000 kgs1

Langton is a low-cost high-efficiency facility with a natural gas well

and cogeneration facility on site, in addition to having all water

recycled through a bio-pond. As a bonus, the incorporation of our

Artificially Intelligent Master Grower, a highly automated system,

allows for our labour force to be at a fraction of the costs of our

competitors.

CAN AD A

13

Langton is a low-cost high-efficiency facility

P H AR M AC Y I N I TI ATI VE

Partnerships

We’ve teamed up with national and regional pharmacy operators

Education

We offer an accredited program (CCCEP)for pharmacisits. Launched October 1 2018. See Press Release

National

Canada-wide participation through a large retail banner network

Training

Pharmacists are trained in the field of medicinal cannabis to better serve their customers

14

R ECE NT U P DATE S

P R OV I N C IA L AG R E E M EN T S

Manitoba Wayland is pleased to announce that on June 28, 2018, it has signed a supply agreement with the Manitoba Liquor & Lotteries Corporation

(“MBLL”) to make available for purchase by MBLL at least 550 kg of various cannabis products during the first twelve months of the agreement.

Alberta Wayland is pleased to announce that it has entered into an agreement with the Alberta Gaming, Liquor & Cannabis Commission (AGLC) to allocate

up to 3,375 kg of cannabis product for the AB market within the first six months.

British Columbia Wayland is pleased to announce that it has been selected by the BC Liquor Distribution Branch (“BCLDB”) to enter into a memorandum of

understanding (“MOU”) as a preferred licensed producer to initially supply approximately 3,621,900g (~3,622kg) of non-medical cannabis to BCLDB over the first 12 months following legalization.

Ontario Wayland is pleased to announce that the Company has been selected by The Ontario Cannabis Store (“OCS”) to supply a variety of safe, high quality

cannabis products through its online store launching October 17, 2018.

U P DAT E S

10/17/18 Wayland Releases Portfolio of Brands & Receives Sales License from Health Canada for Expansion Site

10/15/18 Wayland signs Minimum 9,000kg supply agreement with Cannamedical for export of product from Canada to Germany

10/5/18 Wayland successfully exports THC distillate from Canada to Switzerland

10/4/18 Wayland launches Medical Cannabis Professional education Program for Pharmacists

10/2/18 Wayland announces filing of Final Short Form Prospectus in connection with Special Warrant Offering

9/27/18 Wayland announces plans for first retail location in Zurich, Switzerland

9/24/18 Maricann Group Inc. Announces intent to change name to Wayland Group Corporation

9/17/18 Maricann launches Kiwi – Simplifying Cannabis for Recreational Consumers

15

C AP I TAL I Z ATI O N TABL E

FULLY DILUTED SHARE COUNT 213,195,713

COMMON SHARES OUTSTANDING 139,127,571

SPECIAL WARRANTS 23,376,100

COMMON SHARES TO BE ISSUED 665,707

COMPENSATION OPTIONS 1,101, 330

CONVERTIBLE DEBENTURE CONVERSION 13,873,304

WARRANTS 21,836,637

NANOLEAF ADJUSTMENT CLAUSE 2,552,989

SHARE RIGHTS 1,240,231

STOCK OPTIONS 9,421,844

16

As of August 14 ,2018

Ticker: CSE:

OTCQB:

FRANKFURT:

WAYL

MRRCF

75M

President

Terry FretzTerry Fretz is a long-timepharmaceutical executive, Terry wasintegral in establishing and runningtwo privatelyheld generic pharmaceuticalcompanies. Under hisleadership, both organizations wererecognized as the fastest growingpharma companies in Canada. Bothcompanies were subsequentlyacquired by publicly tradedmultinationals. Terry served asPresident and General Manager ofWatsonPharmaceuticals - Canada beforeassuming his responsibilities asPresident at Wayland.

TH E WAY L AN D TE AM

CEO & Director

Benjamin WardBen leads all facets of thecompany’s operations, includingits strategic direction and execution,finance and industry relations. Hebrings extensive domestic and globalexperience in business development,

infrastructure developmentand capital markets to hisleadership of Wayland. Ben holds aBA (Honors) and an MBA fromBradford University School ofManagement (England), the latterwith a dual concentration inOperations and Finance.

CFO

Scott LangilleScott has over 30 years ofexperience in the pharmaceuticalindustry in both Canada and theUnited States. Scott has held CFOpositions at publiclytradedcompanies

pharmaceutical including Tribute

Pharmaceuticals, andVirexx Medical Corp. Pastfinancial experience includesVice President at BiovailPharmaceuticals Inc. and Director,Corporate Finance at BiovailCorporation. Scott has a professionalaccounting designation and an MBAfromthe University of Toronto.

VP, Sales & Marketing

17

Geoff KosarGeoff has played a key role inshaping the marketing and strategicdirection of many iconic householdbrands in Canada for the past 20years. Most recently, he was theHead of Marketing at Diageo,Canada’s largest Spirits company.Geoff understands selling andmarketing brands in regulatedindustries.

VP, Communications

Graham FarrellGraham has been deeply involved withthe capital markets for more than 15years. Prior to joining Wayland, Mr.Farrell worked in every aspect of theinvestment banking business, fromrunning an equity trading desk tofinancing public companies. Grahamstudied Political Science at theUniversity of Waterloo.

VP, Global Infrastructure

Jeff AyotteJeff leads Wayland’s GlobalInfrastructure which includethe Company’s Engineeringand Construction departments. Over18 years of experience deliveringsuccessfully complex infrastructureprojects while providing majorreturns on investment. Jeff’ssuccessful deliveries include industrysectors such as Pharmaceutical,Medical, Food and Beverage, andEnergy conservation initiatives withHospitals and Universities. Jeff’sglobal reach has contributed to thedesign, engineering, andconstruction of various cannabisfacilities around the world.

Director, Supply Chain &Operations

Veronica LeschVeronica has 20 yearsof experience in projectmanagement and supply chainin pharmaceutical, consumerpackaged goods and retail pharmacyindustries, including Apotex, Johnson& Johnson and Shoppers Drug Mart.As an operational leader, she hasproven successes within fast- paceddynamic environments in bothdomestic and international markets.Veronica is PMP certified and holds aBA (Honors) from Trinity College,University of Toronto.

Director, National Sales

Sanjay PatelSanjay is responsible for leading ourcommercial sales strategy for boththe recreational and medicalmarkets in Canada. Sanjay bringswith him a successful track record ofselling to Liquor Boards and privatebeverage alcohol customers inCanada. Sanjay has worked with bothDiageo Canada and Molson CoorsCanada, in various roles includingsales, business analytics and strategy.Sanjay holds a Bachelors of Sciencein Management (BSM) degree, witha concentration in Finance, from theUniversity of Massachusetts, and anMBA from the Schulich School ofBusiness.

TH E WAY L AN D TE AM

18

Interim Chair

Paul PathakPaul Pathak is a partner at ChitizPathak LLP, a Toronto law firm. Paulpractices principally in the areas ofcorporate, securities, corporatefinance, mergers and acquisitionsand commercial law. He representsand provides sophisticated guidanceto private and public corporateclients in a broad range of industries,including mining, technology,cannabis, manufacturing, venturecapital and merchant banking.

Director

Michael SteinMichael Stein currently actsas a financial consultant andadvises clients on variousmatters, including acquisitions,divestitures, corporatefinancings, reorganizationsand restructurings. Mr. Stein iscurrently the President, Secretary anddirector of Applied InventionsManagement Corp. He is formerDirector of U.S. Money Market for afederally chartered Trust companyand former institutional moneybanker for a U.S. Savings and LoanAssociation based in California. Mr.Stein majored in economics andgraduated with a Bachelor of Artsfrom York University.

Director

Gerhard MüllerPast partner of Ernst and Young’sGerman practice, Gerhard wasresponsible for the Technology,Media & Entertainment sector atErnst & Young for the Germany,Switzerland, Austria (GSA) Region.Gerhard is a Certified Public Auditorand Tax consultant who studiedeconomics and English in Munich andManchester (UK). He is the deputychairman of m4e AG, a Germanlisted Media company. Gerhard is anindependent member of thecompany’s Board of Directors.

Director

Eric SilverWith extensive experience usingmedical cannabis to treat chronicpain, Dr. Silver co-founded L.E.Medical in 2002, a nutraceutical andnatural health supplement company.Dr. Silver is an Assistant Professor andClinical Teacher in the Department ofFamily and Community Medicine atthe University of Toronto. He is amember of the College of FamilyPhysicians of Canada, with a focusedpractice in interventional painmanagement.

TH E WAY L AN D TE AM

19

Medical

Professor Dr. Markus Backmund MD, PhD

Chair of German Society of AddictionMedicine, Professor of MedicineLudwig Maximilians UniverstätMunchen, Head of PIT, Editor of themagazine Suchtmedizin (Journal ofAddiction Medicine), President of theinterdisciplinary congress ofAddiction Medicine, Munich (800Medical Doctors) and various otherpositions mainly relating to addictionresearch and drug and alcoholdependency.

Public Policy

Birgit HomburgerCurrently heading the Berlin officeof the Deutsche Aktieninstitute.V and senior advisor in aninternational executive searchcompany. Ms. Homburger is therecent past chair of the FreieDemokratische Partei, member of theFederal Coalition committee,member of the Bundestag up to2013, Chairwoman of the FDPparliamentary group in theBundestag, and leader of theparliamentary group with93 members of the GermanBundestag, responsible for over 110staff.

Legal

Dr. Horst SchiesslMember of the Board ofthe Dussmann Stifting andIndependent Chair of the supervisoryboard of Baader Bank AG. Dr.Schiessl, founding partner of SSPSchwiessl, is a lawyer with more thanforty years of experience inconsulting and advising largerGerman companies and familyoffices. He studied law andeconomics in Munich.

Insurance, Technology

Hans DendlPast Chairman of AOK Health,Researcherat NASAJet PropulsionLaboratory (JPL), and LockheedMartin Aeronautical Research. Mr.Dendl is currently a lecturer atLudwig Maximilians UniverstätMunchen (LMU) — MSc. He holds adegree from the MassachusettsInstitute of Technology (MIT)

WAY L AN D G MB H AD VI S O RY B OAR D

20

Wayland Group Inc.

Graham Farrell

VP, Communications graham.farrell@waylandgroup.com 647-643-7665

Corporate Headquarters (Canada)

Wayland Group Inc.

845 Harrington Court, Unit 3

Burlington, Ontario L7N 3P3

Canada

289-288-6274

European Headquarters (Germany)

Maricann GmbH

Thierschstrasse 3, 80538 Munchen

Deutschland

waylandgroup.com

C ON TA C T IN F OR M AT I O N

21